The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 10)
Research Grant, 2017
It is well known that the alpha-synuclein protein clumps in the cells of people with Parkinson's disease (PD), but it is unclear what prompts it to clump. Researchers believe that in PD the structure and amount of alpha-synuclein molecules differs from that in healthy cells, and these differences make alpha-synuclein in PD sticky, i.e., prone to clumping. We will use the MJF-14 an...
Access to Data and Biospecimens, 2014
Increased inflammation is associated with the progression and possibly even onset of Parkinson's disease (PD). Mutations in the LRRK2 gene are also associated with PD, and recent evidence points to a role for LRRK2 to modulate inflammatory pathways. This project aims to investigate inflammatory cytokines (small proteins involved in cell signaling) in people with LRRK2 mutations...
Research Grant, 2014
Mutations in LRRK2 are a major genetic cause of Parkinson's disease. This study aims to determine what happens to the amount of LRRK2 protein in the brains of people with Parkinson's disease.
The project will use standard techniques to measure the amount of LRRK2 in a large number of donor brains sourced throughout the world. We will determine if the amount...
Mutations in the LRRK2 gene are a common cause of genetic Parkinson's disease. LRRK2 is highly expressed in circulating and tissue immune cells. We have recently identified that LRRK2 is a component of the pathways involved in innate immunity. We aim to identify whether LRRK2 has a role in innate immunity using blood immune cells from donors with and without Parkinson's disea...
Rapid Response Innovation Awards, 2010
- In animal models of PD, brain injections of certain neurotrophic factors prevent degeneration of midbrain dopaminergic neurons.
- Clinical testing of brain injected gene vectors expressing these neurotrophic factors is underway.
- Frequent intranasal dosing with neurotrophic factor (protein) is also therapeutic in animal models.
- This project will test whether a single intr
Researchers: Ian Andrew Ferguson, PhD, MBA